PubRank

Michael R Lassen

Author PubWeight™ 61.58‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 16.17
2 Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 11.84
3 Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009 6.83
4 Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012 5.25
5 Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002 3.96
6 Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006 3.58
7 Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002 2.26
8 Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003 2.22
9 Prevention of venous thromboembolism. Chest 2005 1.76
10 Fondaparinux, the first selective factor Xa inhibitor. Curr Opin Hematol 2003 1.06
11 A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. Thromb Haemost 2013 0.97
12 Prothrombin fragment 1+2 in urine as an indicator of sustained coagulation activation after total hip arthroplasty. Thromb Res 2007 0.84
13 Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. Vasc Health Risk Manag 2012 0.83
14 Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. Chest 2004 0.80
15 New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. Chest 2003 0.80
16 Thrombin split products (prothrombin fragment 1 + 2) in urine in patients with suspected deep vein thrombosis admitted for radiological verification. Thromb Res 2013 0.78
17 Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial. Ann Surg 2014 0.78
18 Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res 2008 0.77
19 Efficacy of fondaparinux for thromboprophylaxis in hip fracture patients. J Arthroplasty 2004 0.77
20 Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). Thromb Haemost 2013 0.76
21 Urinary Prothrombin Fragment 1+2 in relation to Development of Non-Symptomatic and Symptomatic Venous Thromboembolic Events following Total Knee Replacement. Thrombosis 2011 0.75
22 Prophylaxis for the thromboembolic disease--recommendations from the American College of Chest Physicians--are they appropriate for orthopaedic surgery? J Arthroplasty 2006 0.75
23 Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery. Lancet 2003 0.75
24 Fondaparinux. J Am Acad Orthop Surg 2004 0.75
25 Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism. Curr Opin Pulm Med 2002 0.75
26 A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J South Orthop Assoc 2002 0.75
27 A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist. J South Orthop Assoc 2002 0.75
28 Assessment of HIT antibody complex in hip fracture patients receiving enoxaparin or unfractionated heparin. Clin Appl Thromb Hemost 2012 0.75
29 Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients. Arch Pathol Lab Med 2003 0.75